CD8A and neoplasm: Furthermore, when 7HP349 was combined with anti–CTLA-4 therapy, infiltration of CD8+ effector T cells in anti–programmed death 1–resistant (anti–PD-1)-resistant tumors was enhanced, and facilitated tumor regression (98).